These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 11400948)

  • 1. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
    Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WJ; Weisdorf DF
    Biol Blood Marrow Transplant; 2001; 7(5):265-73. PubMed ID: 11400948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide for treatment of patients with chronic graft-versus-host disease.
    Koc S; Leisenring W; Flowers ME; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ
    Blood; 2000 Dec; 96(12):3995-6. PubMed ID: 11090092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
    Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
    Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide as salvage therapy for chronic graft-versus-host disease.
    Parker PM; Chao N; Nademanee A; O'Donnell MR; Schmidt GM; Snyder DS; Stein AS; Smith EP; Molina A; Stepan DE; Kashyap A; Planas I; Spielberger R; Somlo G; Margolin K; Zwingenberger K; Wilsman K; Negrin RS; Long GD; Niland JC; Blume KG; Forman SJ
    Blood; 1995 Nov; 86(9):3604-9. PubMed ID: 7579470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
    Koc S; Leisenring W; Flowers ME; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Storb R; Appelbaum FR; Martin PJ
    Blood; 2002 Jul; 100(1):48-51. PubMed ID: 12070007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic graft-versus-host disease: a prospective cohort study.
    Arora M; Burns LJ; Davies SM; Macmillan ML; Defor TE; Miller WJ; Weisdorf DJ
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):38-45. PubMed ID: 12533740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of budesonide mouthwash on oral chronic graft versus host disease.
    Sari I; Altuntas F; Kocyigit I; Sisman Y; Eser B; Unal A; Fen T; Ferahbas A; Ozturk A; Unal A; Cetin M
    Am J Hematol; 2007 May; 82(5):349-56. PubMed ID: 17109390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
    Wagner JL; Seidel K; Boeckh M; Storb R
    Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
    Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG
    Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
    Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
    Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
    Sullivan KM; Witherspoon RP; Storb R; Deeg HJ; Dahlberg S; Sanders JE; Appelbaum FR; Doney KC; Weiden P; Anasetti C
    Blood; 1988 Aug; 72(2):555-61. PubMed ID: 3042042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease.
    Cragg L; Blazar BR; Defor T; Kolatker N; Miller W; Kersey J; Ramsay M; McGlave P; Filipovich A; Weisdorf D
    Biol Blood Marrow Transplant; 2000; 6(4A):441-7. PubMed ID: 10975513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
    Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
    Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide for the treatment of chronic graft-versus-host disease.
    Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
    N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of chronic graft-v-host disease in a rat model.
    Vogelsang GB; Hess AD; Friedman KJ; Santos GW
    Blood; 1989 Jul; 74(1):507-11. PubMed ID: 2752128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
    Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
    Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
    Sullivan KM; Witherspoon RP; Storb R; Weiden P; Flournoy N; Dahlberg S; Deeg HJ; Sanders JE; Doney KC; Appelbaum FR
    Blood; 1988 Aug; 72(2):546-54. PubMed ID: 3042041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
    Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ
    Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
    Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.